PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Jeremie Calais; Francesco Ceci; Steve Y Cho; Stefano Fanti; Frederik L Giesel; Karolien Goffin; Uwe Haberkorn; Heather Jacene; Phillip J Koo; Klaus Kopka; Bernd J Krause; Liza Lindenberg; Charles Marcus; Felix M Mottaghy; Daniela E Oprea-Lager; Joseph R Osborne; Morand Piert; Steven P Rowe; Heiko Schöder; Simon Wan; Hans-Jürgen Wester; Thomas A Hope; Ken Herrmann

doi:10.1007/s00259-022-06089-w

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. doi: 10.1007/s00259-022-06089-w. Epub 2023 Jan 5.

Authors

Wolfgang P Fendler^{1

2}, Matthias Eiber³, Mohsen Beheshti⁴, Jamshed Bomanji⁵, Jeremie Calais⁶, Francesco Ceci^{7

8}, Steve Y Cho⁹, Stefano Fanti¹⁰, Frederik L Giesel¹¹, Karolien Goffin¹², Uwe Haberkorn¹³, Heather Jacene¹⁴, Phillip J Koo¹⁵, Klaus Kopka^{16

17

18}, Bernd J Krause¹⁹, Liza Lindenberg²⁰, Charles Marcus²¹, Felix M Mottaghy^{22

23}, Daniela E Oprea-Lager²⁴, Joseph R Osborne²⁵, Morand Piert²⁶, Steven P Rowe²⁷, Heiko Schöder²⁸, Simon Wan⁵, Hans-Jürgen Wester²⁹, Thomas A Hope³⁰, Ken Herrmann³¹

Affiliations

¹ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
² PET Committee of the German Society of Nuclear Medicine, Marburg, Germany.
³ Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
⁴ Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
⁵ Institute of Nuclear Medicine, UCLH NHS Foundation Trust, London, UK.
⁶ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
⁷ Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.
⁸ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
⁹ Department of Radiology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
¹⁰ IRCCS, AOU Bologna, Bologna, Italy.
¹¹ Department of Nuclear Medicine, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
¹² Department of Nuclear Medicine, Division of Nuclear Medicine and Molecular Imaging, University Hospital Leuven, KU Leuven, Louvain, Belgium.
¹³ Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
¹⁴ Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, USA.
¹⁵ Banner MD Anderson Cancer Center, Phoenix, AZ, USA.
¹⁶ Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
¹⁷ School of Science, Faculty of Chemistry and Food Chemistry, Technical University Dresden, Dresden, Germany.
¹⁸ German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
¹⁹ Department of Nuclear Medicine, University Medical Center, University of Rostock, Rostock, Germany.
²⁰ Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
²¹ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.
²² Department of Nuclear Medicine, University Hospital RWTH Aachen University, Aachen, Germany.
²³ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
²⁴ Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
²⁵ Department of Radiology, Division of Molecular Imaging and Therapeutics, Weill Cornell Medicine, New York, NY, USA.
²⁶ Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, University of Michigan, Ann Arbor, MI, USA.
²⁷ Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
²⁸ Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
²⁹ Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meißner-Str. 3, 85748, Garching, Germany.
³⁰ Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
³¹ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. ken.herrmann@uk-essen.de.

Abstract

Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.

Keywords: Guideline; PET; PSMA; Prostate cancer; Restaging; Staging.

MeSH terms

Edetic Acid
Gallium Radioisotopes
Humans
Male
Oligopeptides
Positron Emission Tomography Computed Tomography* / methods
Prostatic Neoplasms* / diagnostic imaging

Substances

Gallium Radioisotopes
Oligopeptides
Edetic Acid